Our reports provide an independent, expert view supported by robust and innovative data interrogation and analysis.

Refine Sector
Sub-Category
Clear
Publish Date
Clear
Region
Clear
Clear All
Sort by:
Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

Published: Jun-2017

Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related.....

$6995
More Info
Frontier Pharma: Dermatology – Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Published: Jun-2017

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct.....

$6995
More Info
Frontier Pharma: Alzheimer’s Disease and Associated Indications – Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

Published: May-2017

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable.....

$6995
More Info
Frontier Pharma: First-in-Class Innovation in Hematological Cancers – Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

Published: May-2017

The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and.....

$6995
More Info
Frontier Pharma: Head and Neck Cancer – Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

Published: Mar-2017

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and.....

$6995
More Info
Frontier Pharma: Fatty Liver Disease – High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Published: Mar-2017

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation.....

$6995
More Info
Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Published: Jan-2017

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly.....

$6995
More Info
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Published: Jan-2017

Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune.....

$6995
More Info
Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Published: Dec-2016

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia.....

$6995
More Info
Frontier Pharma: Hepatitis C – Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Published: Dec-2016

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may.....

$6995
More Info
Sort by: